Astrazeneca annual current ratio
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca Current Ratio Growth & History (AZN)
Astrazeneca's current ratio was 0.94 for fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.94 | 0.01 | +1.22% |
| 2024 | 2024-12-31 | 0.93 | 0.11 | +12.98% |
| 2023 | 2023-12-31 | 0.82 | −0.04 | −4.53% |
| 2022 | 2022-12-31 | 0.86 | −0.30 | −26.02% |
| 2021 | 2021-12-31 | 1.16 | 0.20 | +20.69% |
| 2020 | 2020-12-31 | 0.96 | 0.10 | +12.04% |
| 2019 | 2019-12-31 | 0.86 | −0.10 | −10.23% |
| 2018 | 2018-12-31 | 0.96 | 0.15 | +19.22% |
| 2017 | 2017-12-31 | 0.80 | −0.07 | −7.67% |
| 2016 | 2016-12-31 | 0.87 | −0.21 | −19.25% |
| 2015 | 2015-12-31 | 1.08 | — | — |
Astrazeneca quarterly current ratio
Q4.17
Q2.18
Q4.18
Q2.19
Q4.19
Q2.20
Q4.20
Q2.21
Q4.21
Q2.22
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.89 | 0.02 | +2.71% |
| Q1 2026 | 2026-03-31 | 0.91 | — | — |
| Q4 2025 | 2025-12-31 | 0.94 | 0.01 | +1.22% |
| Q3 2025 | 2025-09-30 | 0.88 | — | — |
| Q2 2025 | 2025-06-30 | 0.86 | −0.03 | −2.92% |
| Q4 2024 | 2024-12-31 | 0.93 | 0.11 | +12.98% |
| Q2 2024 | 2024-06-30 | 0.89 | 0.02 | +2.65% |
| Q4 2023 | 2023-12-31 | 0.82 | −0.04 | −4.53% |
| Q2 2023 | 2023-06-30 | 0.87 | −0.09 | −9.69% |
| Q4 2022 | 2022-12-31 | 0.86 | −0.30 | −26.02% |
| Q2 2022 | 2022-06-30 | 0.96 | −0.27 | −21.88% |
| Q4 2021 | 2021-12-31 | 1.16 | 0.20 | +20.69% |
| Q2 2021 | 2021-06-30 | 1.23 | 0.41 | +49.48% |
| Q4 2020 | 2020-12-31 | 0.96 | 0.10 | +12.04% |
| Q2 2020 | 2020-06-30 | 0.82 | −0.13 | −13.49% |
| Q4 2019 | 2019-12-31 | 0.86 | −0.10 | −10.23% |
| Q2 2019 | 2019-06-30 | 0.95 | 0.23 | +31.15% |
| Q4 2018 | 2018-12-31 | 0.96 | 0.15 | +19.22% |
| Q2 2018 | 2018-06-30 | 0.72 | — | — |
| Q4 2017 | 2017-12-31 | 0.80 | — | — |
Astrazeneca current ratio trends
Over the last five fiscal years, Astrazeneca's current ratio decreased from 0.96 to 0.94, a change of −0.02. The latest reported quarter, Q2 2026, shows 0.89.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...